<DOC>
	<DOCNO>NCT02893358</DOCNO>
	<brief_summary>The primary purpose study estimate target organ protection 12 month antihypertensive treatment mask hypertension patient least one kind target organ damage ( left ventricular hypertrophy , large arterial stiffness microalbuminuria ) . Improvement define relevant parameter back normal decline least 20 % . The secondary objective include : blood pressure lower effect , target organ damage parameter improvement , incidence rate cause death cardiovascular event ( stroke myocardium infraction ) .</brief_summary>
	<brief_title>Antihypertensive Treatment Masked Hypertension Target Organ Protection</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Masked Hypertension</mesh_term>
	<criteria>1 . Age 3070 year old 2 . Masked hypertension patient , define clinic BP &lt; 140/90 mmHg , 24h ambulatory BP ≥130/80 mmHg ( ) daytime BP ≥135/85 mmHg ( ) nighttime BP ≥120/70 mmHg 3 . Combined least one kind target organ damage : left ventricular hypertrophy ( Cornell voltage combination ≥2440mm·ms SokolowLyon index ≥4.0mv male 3.5mv female ) , large arterial stiffness ( brachialankle pulse wave velocity ≥1400cm/s ) microalbuminuria ( twice random urine microalbuminuria/creatinine ratio ≥2.5mg/mmol male 3.5mg/mmol female ) . 4 . Did n't use antihypertension drug within 2 week 5 . Be willing participate trial able finish clinic visit 1 . Under antihypertensive treatment 2 . Secondary hypertension 3 . Taking medication may influence BP 4 . Sleep apnea syndrome 5 . Diabetes combine microalbuminuria 6 . Renal parenchymal disease , chronic nephritis , polycystic kidney 7 . Occurrence coronary heart disease , myocardial infraction stroke within 6 month 8 . Structural heart disease , hypertrophic cardiomyopathy , dilate cardiomyopathy 9 . Alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , total bilirubin ( TBL ) upper twice normal range , serum creatinine ( Scr ) ≥2.0mg/dl , plasma hypokalemia≥5.5mmol/L , 10 . Patients contraindication angiotensin receptor blocker ( ARBs )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Allisartan Isoproxil</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>large arterial stiffness</keyword>
	<keyword>microalbuminuria</keyword>
</DOC>